{"nctId":"NCT02459080","briefTitle":"Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2015-09"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":619,"armGroups":[{"label":"TD-4208-1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: TD-4208"]},{"label":"TD-4208-2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: TD-4208"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"TD-4208","otherNames":["revefenacin"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is a male or female subject 40 years of age or older\n\nExclusion Criteria:\n\n* Females who are pregnant, lactating, breast-feeding or planning to become pregnant during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Trough FEV1 on Day 85","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.81","spread":"15.095"},{"groupId":"OG001","value":"126.85","spread":"15.389"},{"groupId":"OG002","value":"-19.41","spread":"16.108"}]}]}]},{"type":"SECONDARY","title":"Summary of Trough FEV1 Overall Treatment Effect From Day 15 to Day 85","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.0","spread":"3.10"},{"groupId":"OG001","value":"124.8","spread":"3.20"},{"groupId":"OG002","value":"-30.8","spread":"3.18"}]}]}]},{"type":"SECONDARY","title":"Summary of Change From Baseline to Peak FEV1 After First Dose","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"218.14","spread":"9.546"},{"groupId":"OG001","value":"224.46","spread":"9.744"},{"groupId":"OG002","value":"91.79","spread":"9.963"}]}]}]},{"type":"SECONDARY","title":"Summary of Rescue Medication Use: Puffs Per Day","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.26","spread":"0.234"},{"groupId":"OG001","value":"2.27","spread":"0.239"},{"groupId":"OG002","value":"2.72","spread":"0.246"}]}]}]},{"type":"SECONDARY","title":"Percentage of Albuterol Rescue-free 24-hour Periods","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.35","spread":"2.784"},{"groupId":"OG001","value":"43.57","spread":"2.829"},{"groupId":"OG002","value":"45.21","spread":"2.890"}]}]}]},{"type":"SECONDARY","title":"St. George's Respiratory Questionnaire (SGRQ) Proportion of Responders on Day 85","description":"A Responder is defined as someone who experienced a decrease in SGRQ score of 4 or more units","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"46","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":212},"commonTop":["Chronic Obstructive Pulmonary Disease","Cough","Dyspnoea","Headache","Upper respiratory tract infection"]}}}